Simon Mason to Lead NESTcc

The National Evaluation System for health Technology Coordinating Center (NESTcc), an initiative of the Medical Device Innovation Consortium (MDIC), has named Simon Mason as its new president. In his new role, Mason will lead strategy and operations for NESTcc to serve its stakeholders, including patients, providers, payers, medical device manufacturers, regulators, and others.
 
With a 30-year career spanning roles in executive management as well as product and business development, Mason joins NESTcc from Pharmaspectra, a business acquired by IQVIA, where he most recently served as chief operating officer. At Pharmaspectra, he led development and commercialization of a data lake of scientific and medical affairs information utilized by pharmaceutical and medical device companies.
 
“I’m honored to join the team at NESTcc and work with this organization’s network collaborators, partners, customers and other stakeholders to change the paradigm of clinical research through the appropriate use of real-world evidence,” Mason said. “Together, we will drive continued innovation for the benefit of patients and all medical device stakeholders.”
 
NESTcc is focused on advancing the use of medical device real-world evidence (RWE), and Mason’s experience in building healthcare data businesses positions him strongly to advance NESTcc’s mission. As president, he will lead NESTcc’s continued development of a trusted not-for-profit platform for the timely generation of RWE and its collaborative work on advancing RWE methodologies to address pre- and post-market challenges in the medical technology space.
 
“We’re thrilled to welcome Simon to NESTcc to build on the organization’s strong foundation and accelerate its development to support medical device innovation,” MDIC President/CEO Andrew Fish, J.D., said. “Simon’s operational and commercialization expertise make him an excellent candidate to lead NESTcc’s work in advancing the use of real-world evidence for the benefit of patients and all medical device stakeholders.” 
 
“Simon is an innovator and accomplished leader in building healthcare data companies, and I’m excited to collaborate with him to guide NESTcc’s strategic priorities and deliver ever greater value for stakeholders across the medical device ecosystem,” said Diane Wurzburger, chair of the NESTcc Governing Committee and executive of Regulatory Affairs and Quality for GE Healthcare.

“CDRH congratulates Simon in his new role as the President of NESTcc,” said Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health (CDRH). “We look forward to working with Simon and leveraging his expertise to support our shared goal of advancing medical device safety and innovation.”

In 2016, the U.S. Food and Drug Administration awarded the MDIC funding to establish the National Evaluation System for health Technology Coordinating Center (NESTcc). NESTcc is advancing the use of real-world evidence (RWE) in medical devices for regulatory decision-making and committed to transforming the way medical device technologies are tested, approved, and monitored. The Coordinating Center combines RWE system infrastructure with the unparalleled expertise of its network collaborators to accelerate patients’ access to safe and effective medical technology and provide Quality Evidence by Design. 
 
Founded in 2012, MDIC is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to break down barriers in the medical technology life cycle to accelerate innovation and adoption of safe, effective and high-quality medical technologies. The consortium brings together medical technology manufacturers, researchers, regulators, payers, patients and health care providers as trusted collaborators to solve complex challenges in the scientific and technical disciplines that propel medical technology development, approval, adoption and access. MDIC’s work improves regulatory pathways, advances medical device quality, enhances patient safety and access, and facilitates the development of better evidence for approval, coverage and utilization decisions.